Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
IPO Year:
Exchange: NASDAQ
Website: evogene.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $8.00 → $7.00 | Outperform | RBC Capital |
| 10/8/2021 | $7.00 | Buy | ROTH Capital |
| 8/23/2021 | $8.00 | Outperform | RBC Capital |
| 7/29/2021 | $10.00 | Buy | Aegis Capital |
Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe
Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe
Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform. The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions. Lavie
Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In
Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's
Initial fungicidally active compounds already discovered REHOVOT, Israel, Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced the breakthrough discovery of a novel Mode of Action (MoA) active against Zymoseptoria tritici, the fungal pathogen responsible for Septoria tritici blotch (STB), one of the most devastating diseases affecting wheat crops globally. Through extensive virtual screening of large compound libraries and subsequent experimental testing, the company has already identified promising compounds (small molecules) that effect
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023.In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023. The revenues in Q3 2024 are mainly based on Casterra's seed sales. The revenues in Q3 2023 included a license fee payment of $2.5 million received by Lavie Bio.For the full year 2024, Evogene anticipates continued revenue growth, compared to the previous year, mainly due to Casterra's supply of existing seed orders.G&A expenses in Q3 2024
LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel, Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew. Over three years of field trials across Europe, evaluating the efficacy of LAV321 in protecting crops from fungal diseases, LAV321 demonstrated an impressive average efficacy rate of 70% against downy mildew in grapes. These results lead to the decision to advance it to the last stage of product development toward commercialization. Dow
Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced the commercial expansion of Yalos® seed-treatment to soybean, following successful field trials performed in 2024 in the US. Yalos®, Lavie Bio's first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean. Yalos® is comprised of two novel microbes that together improve early vigor, biomass, root and shoot development, and nutrient availability. It aims to imp
Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe
Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe
Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023.In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023. The revenues in Q3 2024 are mainly based on Casterra's seed sales. The revenues in Q3 2023 included a license fee payment of $2.5 million received by Lavie Bio.For the full year 2024, Evogene anticipates continued revenue growth, compared to the previous year, mainly due to Casterra's supply of existing seed orders.G&A expenses in Q3 2024
Zoom conference call scheduled for November 21, 2024, 9:00 AM ET REHOVOT, Israel, Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance:https://us06web.zoom.us/webinar/register/WN_pG-Wc0JeQIifu1dmSUYOng The entire conference will be available online on the compa
Conference call and webcast: today, August 22, 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023.Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million.H1 2024 loss $9.8M, down from $14.8M in H1 2023; Q2 2024 loss $6.0M, down from $7.8M in Q2 2023.Projected 2024 cash usage (excl. Biomica & Lavie Bio) $8.0M, down 36% from $12.5M in 2023.Implemented a 10:1 reverse stock split during July 2024.Casterra: Rece
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024. Later that day, Company management, will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_K5GBuG1FQ7Srbe_UJ7r2iQ The entire conference will be available online on the company's website a fe
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel, July 23, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024. The Company's Ordinary Shares will begin trading on the Nasdaq Capital
Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.Q1 2024 net loss: $3.8M vs. $7.0M in Q1 2023.Projected 2024 cash usage, excluding Lavie Bio and Biomica: $8.0M, down 36% from $12.5M in 2023.Ceasing Canonic's operations results in annualized savings of approximately $1.5 million.Casterra's new agreements with African and Brazilian castor seed growers secure 900 tons of castor seeds, expected to fulfill all standing orders by end of 2024.Biomica to present preliminary Phase 1 clinical trial results for BMC128 at the 2024 ASCO conference on June 3.Lavie Bio received
6-K - Evogene Ltd. (0001574565) (Filer)
6-K - Evogene Ltd. (0001574565) (Filer)
EFFECT - Evogene Ltd. (0001574565) (Filer)
POS AM - Evogene Ltd. (0001574565) (Filer)
S-8 - Evogene Ltd. (0001574565) (Filer)
20-F - Evogene Ltd. (0001574565) (Filer)
424B3 - Evogene Ltd. (0001574565) (Filer)
6-K - Evogene Ltd. (0001574565) (Filer)
6-K - Evogene Ltd. (0001574565) (Filer)
424B3 - Evogene Ltd. (0001574565) (Filer)
RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously
ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00
RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00
Aegis Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $10.00
Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make
Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l
REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves as a member of Evogene Ltd.'s board of directors since March 2019, brings a wealth of expertise and a deep commitment to advancing environmentally friendly agricultural technologies. With over 25 years of experience in the agricultural industry, Dr. Adrian Percy strongly advocates for environmentally friendly agricultural and f
REHOVOT, Israel, March 29, 2023 /PRNewswire/ -- Lavie Bio Ltd. ("Lavie Bio"), a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today is pleased to announce the appointment of Mr. Amit Noam as Chief Executive Officer ("CEO") of Lavie Bio, effective as of April 16, 2023. Mr. Noam has extensive experience as a senior executive, particularly in the agriculture and healthcare sectors, leading teams in the development and execution of commercialization strategies, driving long-term growth and value-creatio
REHOVOT, Israel, Sept. 14, 2022 /PRNewswire/ -- Lavie Bio Ltd. ("Lavie Bio"), a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN), (TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced the appointment of Guri Oron as Chief Executive Officer ("CEO") of Lavie Bio, effective as of September 18, 2022. Mr. Oron is a veteran executive in multi-disciplinary, deep-tech organizations, leading medical device and ag-tech companies from inception to market. He brings over 20 years of extensive experience at various early-stage technology companies both
This addition to Biomica's scientific expertise will support the company's upcoming steps in its immuno-oncology clinical development program REHOVOT, Israel, July 28, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced that Professor Gal Markel, Director of the Davidoff Cancer Center & Deputy Director General of the Rabin Medical Center at Clalit Health Services in Israel, is joining Biomica's Scientific Advisory Board. Professor Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology
REHOVOT, Israel, June 23, 2021 /PRNewswire/ --Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that its Board of Directors has resolved to appoint Ms. Sarit Firon to serve as Chairperson of the Board following, and subject to, her re-election as a Director at Evogene's upcoming Annual General Meeting. Mr. Martin Gerstel, Evogene's current Chairperson, recently informed the Board that after almost two decades as the Chairperson, he does not intend to stand for re-election. Mr. Martin Gerstel said: "I am extremely proud of Evogene's journey from its esta
REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced the appointment of Mr. Russ Putland as Vice President Commercial. Russ's significant commercial experience includes more than 30 years of leadership within large multinational agriculture companies. In his last leadership role, he led a sales organization at DuPont crop protection, accountable for $175 million in sales annually. Russ brings a broad understanding of the commercial value cha
SC 13G/A - Evogene Ltd. (0001574565) (Subject)
SC 13G - Evogene Ltd. (0001574565) (Subject)
SC 13G/A - Evogene Ltd. (0001574565) (Subject)
SC 13G/A - Evogene Ltd. (0001574565) (Subject)
SC 13G/A - Evogene Ltd. (0001574565) (Subject)
SC 13G/A - Evogene Ltd. (0001574565) (Subject)
SC 13G/A - Evogene Ltd. (0001574565) (Subject)